Securities Registration: Employee Benefit Plan (s-8)
March 04 2021 - 7:37AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 4, 2021
Registration
No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Dyne Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware
|
|
36-4883909
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
830 Winter Street
Waltham, Massachusetts
|
|
02451
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
2020 Stock Incentive Plan
(Full Title of the Plan)
Joshua T. Brumm
President and Chief Executive Officer
830 Winter Street
Waltham, Massachusetts 02451
(Name and Address of Agent for Service)
(781) 786-8230
(Telephone Number, Including Area Code, of Agent for Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☒
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Securities to be Registered
|
|
Amount
to be
Registered(1)
|
|
Proposed
Maximum
Offering Price
Per Share
|
|
Proposed
Maximum
Aggregate
Offering Price
|
|
Amount of
Registration Fee
|
Common stock, $0.0001 par value per share
|
|
2,272,345 shares(2)
|
|
$18.23(3)
|
|
$41,424,850(3)
|
|
$4,520
|
|
|
(1)
|
In accordance with Rule 416 under the Securities Act of 1933, as amended (the Securities Act), this
registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
|
(2)
|
Consists of 2,272,345 additional shares issuable under the 2020 Stock Incentive Plan.
|
(3)
|
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the
Securities Act and based upon the average of the high and low sales price of the registrants common stock on the Nasdaq Global Select Market on March 1, 2021.
|
Statement of Incorporation by Reference
This Registration Statement on Form S-8, relating to the 2020 Stock Incentive Plan (the 2020 Plan) of Dyne
Therapeutics, Inc. (the Registrant), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8
relating to the 2020 Plan has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference
the contents of the Registration Statement on Form S-8, File
No. 333-248873, relating to the 2020 Plan filed by the Registrant with the Securities and Exchange Commission on September 17, 2020.
Item 8. Exhibits.
The following exhibits are
incorporated herein by reference:
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of
Massachusetts on this 4th day of March, 2021.
|
|
|
DYNE THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Joshua Brumm
|
|
|
Joshua Brumm
|
|
|
President and Chief Executive Officer
|
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Dyne Therapeutics, Inc., hereby severally constitute and appoint Joshua Brumm and Richard
Scalzo, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and
all capacities, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement,
and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Dyne Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the
Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
/s/ Joshua Brumm
Joshua Brumm
|
|
President, Chief Executive Officer and Director
(principal executive officer)
|
|
March 4, 2021
|
|
|
|
/s/ Richard Scalzo
Richard Scalzo
|
|
Vice President of Accounting and
Administration
and Treasurer
(principal financial and accounting officer)
|
|
March 4, 2021
|
|
|
|
/s/ Jason Rhodes
Jason Rhodes
|
|
Director and Chairman of the Board
|
|
March 4, 2021
|
|
|
|
/s/ Ed Hurwitz
Ed Hurwitz
|
|
Director
|
|
March 4, 2021
|
|
|
|
/s/ Dirk Kersten
Dirk Kersten
|
|
Director
|
|
March 4, 2021
|
|
|
|
/s/ Lawrence Klein, Ph.D.
Lawrence Klein, Ph.D.
|
|
Director
|
|
March 4, 2021
|
|
|
|
/s/ David Lubner
David Lubner
|
|
Director
|
|
March 4, 2021
|
|
|
|
/s/ Catherine Stehman-Breen, M.D.
Catherine Stehman-Breen, M.D.
|
|
Director
|
|
March 4, 2021
|
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jul 2023 to Jul 2024